Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine ...
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …
Tardive Dyskinesia Treatment | AUSTEDO XR® (deutetrabenazine)
Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …
Austedo: Regaining Control Over Uncontrolled Movements in ...
Jul 16, 2024 · Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.
FDA Approves One Pill, Once-Daily Tablets of Deutetrabenazine ...
May 30, 2024 · Key Takeaways Deutetrabenazine (Austedo XR) is now available as a once-daily, extended-release tablet for tardive dyskinesia and Huntington disease chorea, enhancing dosing …
Austedo XR Approved: A New Treatment Option for Tardive ...
May 30, 2024 · The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended ...
May 29, 2024 · U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular …
AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
Patients Taking AUSTEDO XR® (deutetrabenazine) - GlobeNewswire
Sep 21, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.
FDA approves new doses of Austedo XR for tardive dyskinesia ...
Jun 3, 2024 · The FDA has approved Austedo XR in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with Huntington’s disease, according to the manufacturer. …